1. Search Result
Search Result
Results for "

receptor-associated

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

3

Peptides

26

Recombinant Proteins

7

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P5964A

    GABA Receptor Neurological Disease
    K1 peptide TFA is a high-affinity peptide ligand for GABAA receptor-associated protein (GABARAP) .
    K1 peptide TFA
  • HY-13277
    IRAK inhibitor 3
    1 Publications Verification

    IRAK Inflammation/Immunology
    IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
    IRAK inhibitor 3
  • HY-13329
    IRAK-1-4 Inhibitor I
    Maximum Cited Publications
    8 Publications Verification

    IRAK-1/4 Inhibitor I

    IRAK Inflammation/Immunology
    IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.2 μM and 0.3 μM, respectively.
    IRAK-1-4 Inhibitor I
  • HY-103017
    JH-X-119-01 hydrochloride
    4 Publications Verification

    IRAK Infection
    JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .
    JH-X-119-01 hydrochloride
  • HY-129967

    Ligands for Target Protein for PROTAC Cancer
    PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .
    PROTAC IRAK4 ligand-1
  • HY-109585

    IRAK Inflammation/Immunology Cancer
    IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .
    IRAK4-IN-7
  • HY-139315

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .
    PROTAC IRAK4 degrader-4
  • HY-139317

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .
    PROTAC IRAK4 degrader-6
  • HY-P5964

    GABA Receptor Neurological Disease
    K1 peptide is a high-affinity peptide ligand for GABAA receptor-associated protein (GABARAP) .
    K1 peptide
  • HY-P5432

    IRAK-1 (360-380)

    IRAK Others
    IRAK-4 Peptide substrate (IRAK-1 (360-380)) is a biological active peptide. (This is a substrate peptide for Interleukin-1 Receptor-Associated Kinase (IRAK) 4)
    IRAK-4 Peptide substrate
  • HY-169057

    IRAK Toll-like Receptor (TLR) Inflammation/Immunology
    BI1543673 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. BI1543673 can reduce the inflammatory response stimulated by TLR4 and TLR7/8 in human lung tissue. BI1543673 can decrease inflammatory signaling in a mouse model of lung inflammation induced by LPS .
    BI1543673
  • HY-114181
    IRAK4-IN-4
    1 Publications Verification

    IRAK Cyclic GMP-AMP Synthase Inflammation/Immunology
    IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM .
    IRAK4-IN-4
  • HY-77048

    IRAK Inflammation/Immunology
    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .
    IRAK-4 protein kinase inhibitor 2
  • HY-158374

    IRAK Inflammation/Immunology
    BIO-8169 is a selective inhibitor for interleukin receptor-associated kinase 4 (IRAK 4), with an IC50 of 0.23 nM. BIO-8169 exhibits good pharmacokinetic character, reduces the production of pro-inflammatory cytokines, and attenuates the autoimmune encephalomyelitis in EAE mice model. BIO-8169 exhibits good blood brain penetrant with a rat Kpu,u of 0.7 .
    BIO-8169
  • HY-161620

    IRAK Inflammation/Immunology
    DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC50 of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .
    DW18134
  • HY-150732

    IRAK Inflammation/Immunology
    IRAK4-IN-18 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 15 nM. IRAK4-IN-18 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-18 can be used for researching arthritis disease .
    IRAK4-IN-18
  • HY-150733

    IRAK Inflammation/Immunology
    IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease .
    IRAK4-IN-19
  • HY-103017A
    JH-X-119-01
    4 Publications Verification

    IRAK Infection Inflammation/Immunology Cancer
    JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .
    JH-X-119-01
  • HY-129966
    PROTAC IRAK4 degrader-1
    1 Publications Verification

    PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively .
    PROTAC IRAK4 degrader-1
  • HY-162538

    NF-κB IRAK PROTACs Inflammation/Immunology
    LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC50 of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) .
    LC-MI-3
  • HY-173025

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 12 (Compound 37) is the agonist for nuclear receptor-associated protein 1 (Nurr1) that activates the transcriptional activity of Nurr1 with an EC50 of 0.06 μM. Nurr1 agonist 12 activates the human response elements NBRE, NurRE, and DR5 with EC50 of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Nurr1 agonist 12 induces the expression of Nurr1-regulated neurotrophic genes, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). Nurr1 agonist 12 exhibits neuroprotective efficacy against Paraquat-induced neurotoxicity .
    Nurr1 agonist 12
  • HY-13276

    IRAK Inflammation/Immunology
    IRAK inhibitor 2 is IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor .
    IRAK inhibitor 2
  • HY-13278
    IRAK inhibitor 4
    1 Publications Verification

    IRAK Inflammation/Immunology
    IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.
    IRAK inhibitor 4
  • HY-13280

    IRAK Inflammation/Immunology
    IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC50 of 160 nM.
    IRAK inhibitor 6
  • HY-101922

    IRAK Inflammation/Immunology
    IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
    IRAK4-IN-1
  • HY-123854

    IRAK Inflammation/Immunology
    PF-06426779 is a potent and selective inhibitor of interleukin‑1 receptor associated kinase 4 (IRAK4), with an IC50 of 0.3 nM .
    PF-06426779
  • HY-13278A

    IRAK Inflammation/Immunology
    IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.
    IRAK inhibitor 4 (trans)
  • HY-148238

    IRAK Inflammation/Immunology
    GNE-2256 (molecule 19) is an orally active IRAK4 (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 Ki=1.4 nM; IL-6 IC50=190 nM) .
    GNE-2256
  • HY-B0799

    Ergoloid mesylates

    GABA Receptor Chloride Channel Adrenergic Receptor Dopamine Receptor Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease
    Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl - channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl - channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .
    Dihydroergotoxine mesylate
  • HY-30008
    Cycloleucine
    5+ Cited Publications

    iGluR Infection Neurological Disease Metabolic Disease Cancer
    Cycloleucine is a specific inhibitor of S-adenosyl-methionine mediated methylation. Cycloleucine is antagonist of NMDA receptor associated glycine receptor, with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine has anxiolytic and cytostatic effects .
    Cycloleucine
  • HY-19836
    Zimlovisertib
    5+ Cited Publications

    PF-06650833

    IRAK Inflammation/Immunology
    Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .
    Zimlovisertib
  • HY-114910

    Prostaglandin Receptor Cancer
    11-Deoxy Prostaglandin E2 is a selective agonist of EP4 with an EC50 of 0.66 nM. 11-Deoxy Prostaglandin E2 is an analog of prostaglandin E2. 11-Deoxy Prostaglandin E2 can be used in study bone healing, heart failure, and other receptor associated conditions .
    11-Deoxy Prostaglandin E2
  • HY-150593

    IRAK Cancer
    IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .
    IRAK4-IN-16
  • HY-111101

    IRAK Cancer
    AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
    AZ1495
  • HY-147696

    HSP AMPK Reactive Oxygen Species Cancer
    SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
    SMTIN-T140

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: